MedSurg and Neurotechnology — Additions and adjustments
Stryker MedSurg and Neurotechnology — Additions and adjustments remained flat by 0.0% to $213.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 183.1%, from $75.25M to $213.00M. Over 3 years (FY 2021 to FY 2024), MedSurg and Neurotechnology — Additions and adjustments shows an upward trend with a 56.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase suggests higher non-recurring costs or restructuring activities, while a decrease indicates a more stable operational environment with fewer extraordinary charges.
Detailed definition
This metric represents non-recurring or non-operational financial adjustments specific to the MedSurg and Neurotechnolog...
Peer comparison
Similar to 'special items' or 'restructuring and other charges' reported by peers in the medical device industry.
syk_segment_medsurg_and_neurotechnology_additions_and_adjustmentsHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $223.00M | $2.32B | $301.00M | $852.00M |
| YoY Change | — | +940.4% | -87.0% | +183.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology — additions and adjustments?
- Stryker (SYK) reported medsurg and neurotechnology — additions and adjustments of $213.00M in Q4 2024.
- How has Stryker's medsurg and neurotechnology — additions and adjustments changed year-over-year?
- Stryker's medsurg and neurotechnology — additions and adjustments increased by 183.1% year-over-year, from $75.25M to $213.00M.
- What is the long-term trend for Stryker's medsurg and neurotechnology — additions and adjustments?
- Over 3 years (2021 to 2024), Stryker's medsurg and neurotechnology — additions and adjustments has grown at a 56.3% compound annual growth rate (CAGR), from $223.00M to $852.00M.
- What does medsurg and neurotechnology — additions and adjustments mean?
- One-time or non-recurring financial charges or adjustments impacting the segment's reported earnings.